Skip to main content
. 2021 Jul 29;16(9):2197–2212. doi: 10.1016/j.stemcr.2021.07.002

Figure 5.

Figure 5

Neuronal network activity after sonlicromanol (KH176) treatment starting from DIV3, in HH1-3 neuronal networks

(A) Representative raster plots of 2-min neuronal network activity recordings at DIV44 of LH1 (n = 17), HH1 vehicle (n = 12), HH1 + 1 μM sonlicromanol (n = 8), HH1 + 3 μM sonlicromanol (n = 5), LH2 (n = 6), HH2 vehicle (n = 16), HH2 + 1 μM sonlicromanol (n = 4), HH2 + 3 μM sonlicromanol (n = 5), LH3 (n = 16), HH3 vehicle (n = 9), HH3 + 1 μM sonlicromanol (n = 14), and HH3 + 3 μM sonlicromanol (n = 10).

(B–D) Quantification of the overall MFR, PRS, and NBR for (B) set #1 including HH1 + 0.5 μM sonlicromanol (n = 5), (C) set #2, and (D) set #3 including HH3 + 0.5 μM sonlicromanol (n = 13). Data represent means ± SEM. We determined the statistical difference between untreated- and sonlicromanol-treated HH1–3 conditions. ∗p < 0.05, ∗∗p < 0.01, ∗∗∗p < 0.001, ∗∗∗∗p < 0.0001, using restricted maximum likelihood model, with Holm-Sidak's correction for multiple comparisons between treated and untreated samples.

See also Figure S3.